Some top-selling drugs that have recently lost or soon will lose patent protection and face generic

Some top-selling drugs that have recently lost or soon will lose patent protection and face generic competition, along with their purpose. The dates are estimates and can change.

2008:

Fosamax, osteoporosis

Imitrex, migraines

Protonix, severe heartburn

Risperdal, schizophrenia/bipolar disorder

2009:

Prevacid, severe heartburn

Topamax, migraine prevention/epilepsy

Valtrex, herpes

2010:

Cozaar/Hyzaar, high blood pressure

Flomax, overactive bladder

2011:

Actos, diabetes

Aricept, Alzheimer’s disease

Effexor XR, antidepressant

Levaquin, bacterial infections

Lipitor, cholesterol

2012:

Lexapro, antidepressant

Plavix, blood thinner

Seroquel, schizophrenia/bipolar disorder

Source: Medco Health Solutions July 2008 report